Jpmorgan Chase & CO Pharma Cyte Biotech, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18 shares of PMCB stock, worth $28. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18
Previous 19
5.26%
Holding current value
$28
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PMCB
# of Institutions
30Shares Held
932KCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6209KShares$328,5470.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$302,0470.0% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$264,0740.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$144,5767.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$129,8810.17% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $32.6M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...